Clinical trial · no report yet · Phase 3
IMpassion050
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- NCT03726879 ↗
- Completed
- Hoffmann-La Roche
- 8 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 4 | |
| X threads | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Breast Cancer
- Interventions
- Atezolizumab; Placebo; Doxorubicin; Cyclophosphamide; Paclitaxel; Trastuzumab; Pertuzumab; Trastuzumab Emtansine
- Arms
- Atezolizumab +ddAC-PacHP · Experimental
- Placebo + ddAC-PacHP · Placebo comparator
- Enrollment
- 454
- Primary outcomes
- Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3)
- pCR in the ITT Population
- Sponsor
- Hoffmann-La Roche with Chugai Pharmaceutical
- Start
- Jan 11, 2019
- Primary completion
- Feb 5, 2021
- Results posted
- Yes
- Registry record
- NCT03726879 · updated Nov 5, 2024
Publications
linked from the registry- Huober J, Barrios CH, Niikura N, Jarzab M, Chang YC, Huggins-Puhalla SL, Pedrini J, Zhukova L, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H; IMpassion050 Trial Investigators. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. J Clin Oncol. 2022 Sep 1;40(25):2946-2956. doi: 10.1200/JCO.21.02772. Epub 2022 Jun 28. PubMed 35763704